Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Not Available].

P Bierling1, B Godeau

  • 1Laboratoire d'Immunologie Leuco-Plaquettaire/Centre de Transfusion et Service de Médecine Interne, Hôpital Henri Mondor, Créteil, France.

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|February 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[French internal medicine is at a turning point in its history. Summary of the 2024 French Internal Medicine meeting].

La Revue de medecine interne·2024
Same author

Intravenous immunoglobulin as a rescue therapy for severe adult autoimmune hemolytic anemia: Results from a French multicenter observational study.

American journal of hematology·2024
Same author

A descriptive study of IgG4-related disease in children and young adults.

Autoimmunity reviews·2022
Same author

[Editorial].

La Revue de medecine interne·2021
Same author

[Immune thrombocytopenia: state of the art and perspectives].

La Revue de medecine interne·2020
Same author

[Challenges and potential solutions in first-line treatments for immune thrombocytopenia in adults].

La Revue de medecine interne·2020
Same journal

Ustekinumab Biosimilars versus Reference Ustekinumab for Moderate-to-Severe Plaque Psoriasis: A Pre-switch Systematic Review and Meta-analysis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Correction: Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Gene Therapy Strategies for Uveal Melanoma: Adeno-associated Virus Delivery Challenges and Translational Opportunities.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Review of Quality Attributes and Analytical Methods Used for Comparative Analytical Assessment of Monoclonal Antibodies as Part of Successful Biosimilar Approvals in the United States and European Union.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Impact of Repeated Antigen Exposure on Humoral Tolerance: Antidrug Antibodies After Single-Dose Versus Multi-dose Adalimumab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

An Overview and Trend Analysis of Biosimilar Approvals in China.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
See all related articles

Autoimmune thrombocytopenic purpura (AITP) treatment with intravenous immunoglobulin (IVIg) can rapidly increase platelet counts, but effects are often temporary. High-dose IVIg is effective for severe cases but has drawbacks, prompting cautious use.

Area of Science:

  • Hematology
  • Immunology
  • Internal Medicine

Background:

  • Autoimmune thrombocytopenic purpura (AITP) is a common nonmalignant disorder characterized by antiplatelet antibodies leading to platelet destruction.
  • AITP presents in acute and chronic forms, with spontaneous remission observed only in the acute type.
  • Life-threatening hemorrhage is a potential complication of AITP.

Purpose of the Study:

  • To evaluate the efficacy and limitations of intravenous immunoglobulin (IVIg) in treating autoimmune thrombocytopenic purpura (AITP).
  • To compare IVIg with Anti-D immunoglobulin for managing AITP.
  • To inform treatment decisions regarding IVIg dosage and patient selection in AITP.

Main Methods:

  • Review of treatment protocols and outcomes for AITP patients receiving IVIg.

Related Experiment Videos

  • Analysis of IVIg administration parameters, including dosage, duration, and immunoglobulin preparation.
  • Comparison of platelet count responses to IVIg versus Anti-D immunoglobulin.

    • Main Results:

    • High-dose IVIg (2 g/kg) frequently induces rapid platelet recovery in severe AITP, particularly when administered over 2 days using intact immunoglobulin concentrates.
    • IVIg's therapeutic effect is typically transient, associated with significant costs and potential adverse effects, leading to reduced dosages and limited use.
    • Repeated IVIg administration may induce prolonged remissions but has not been proven to cure chronic AITP; Anti-D immunoglobulin offers a slower, transient platelet increase.

    Conclusions:

    • IVIg is an effective, rapid-acting treatment for severe AITP, but its transient nature, cost, and side effects necessitate careful patient selection and dosage adjustment.
    • While IVIg can improve platelet counts, it is not a definitive cure for chronic AITP.
    • Anti-D immunoglobulin provides a slower, temporary platelet elevation and is suitable for specific patient groups or when splenectomy is contraindicated.